Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction - Related Studies

Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction

This study has been terminated.

Study NCT00080002. Last updated on June 23, 2005. Information provided by Enzon Pharmaceuticals, Inc.

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer of Stomach
		Gastroesophageal Cancer

2	Additional conditions recognized in this trial
		Neoplasm Metastasis
		Stomach Neoplasms

3	More general conditions related to this trial
		Digestive System Diseases
		Digestive System Neoplasms
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Neoplasms
		Neoplasms by Site
		Neoplastic Processes
		Pathologic Processes
		Stomach Diseases

4	Interventions listed in this trial
		Pegamotecan

5	Additional drug interventions recognized in this trial
		Camptothecin

6	More general drug interventions related to this trial
		Antineoplastic Agents
		Antineoplastic Agents, Phytogenic
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses

7	Sponsors listed in this trial
		Enzon Pharmaceuticals, Inc.